Q-omics provides the consensus-scored MPHOSPH10 profile across patient tissues and cancer cell-line models. MPHOSPH10 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MPHOSPH10 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, MPHOSPH10 protein abundance shows 38,500 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, BLCA, and LSCC as cancer lineages where MPHOSPH10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MPHOSPH10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MPHOSPH10 survival associations across molecular data types. MPHOSPH10 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (7) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MPHOSPH10 RNA expression–survival associations across cancer types. High MPHOSPH10 expression shows unfavorable associations in KIRP, ACC, KICH, LIHC, UVM and COAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MPHOSPH10 RNA expression.
This table summarizes MPHOSPH10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 8. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MPHOSPH10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MPHOSPH10 shows higher tumor expression in BLCA, KIRC, LUSC, LIHC, HNSC and LUAD. The BLCA box plot shows higher MPHOSPH10 RNA expression in tumor versus normal tissue (log2 FC = +0.738, t-test p < 0.001).
This table shows molecular features associated with MPHOSPH10 in patient tissues and cancer cell lines. In patient samples, MPHOSPH10 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MPHOSPH10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
